Cytotoxic profile of CD3+CD20+ T cells in progressive multiple sclerosis.
Mult Scler Relat Disord
; 52: 103013, 2021 Jul.
Article
en En
| MEDLINE
| ID: mdl-34030100
Recently, it was shown that highly effective anti-CD20 therapies used for MS patients not only deplete CD20+ B cells, but also a small subset of T cells expressing CD20 surface marker (CD3+CD20+ T cells). Here we demonstrated that, in progressive MS patients, CD3+CD20+ T cells share the ability to express cytotoxic factors such as perforin and serine-protease granzyme-B (GzmB), classically associated with CD8+ T cells functionality. Beyond it, cluster analyses show that a set of activation markers and transcriptional factors related with CD8 effector program are also expressed in CD3+CD20+ T cells. Further characterization of surface and functional markers from CD3+CD20+ T subsets may be helpful for development of new therapeutic strategies mainly for progressive MS patients, as well as for assessing pathophysiological effects of highly effective anti-CD20 therapies.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple Crónica Progresiva
/
Esclerosis Múltiple
Límite:
Humans
Idioma:
En
Revista:
Mult Scler Relat Disord
Año:
2021
Tipo del documento:
Article
Pais de publicación:
Países Bajos